Efinaconazole impurity is a structurally related synthetic byproduct arising from incomplete alkylation during triazole ring formation. It retains the core 1H-1,2,4-triazole scaffold and 4-fluorophenyl substituent but features a truncated propyl chain with a terminal hydroxymethyl group instead of the parent drug's secondary alcohol. This positional isomer exhibits distinct HPLC retention due to altered hydrophobicity, serving as a critical reference standard for quantifying process-derived impurities in efinaconazole bulk drug substance analysis.
On RequestC1=CC(=C(C=C1F)N2C=NC=N2)Br
InChI=1S/C8H5BrFN3/c9-7-2-1-6(10)3-8(7)13-5-11-4-12-13/h1-5H
WSTLTCNVGOYIRO-UHFFFAOYSA-N